Skip to main content
Clinical Trials/NCT00807521
NCT00807521
Withdrawn
Not Applicable

Reduction of the Cardiac Proapoptotic Stress Response by Dexamethasone in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Amsterdam UMC, location VUmc1 site in 1 countryDecember 2008

Overview

Phase
Not Applicable
Intervention
Dexamethasone
Conditions
Coronary Artery Stenosis
Sponsor
Amsterdam UMC, location VUmc
Locations
1
Primary Endpoint
Expression of p38 in cultured cells and cardiac tissue
Status
Withdrawn
Last Updated
11 years ago

Overview

Brief Summary

The stress response as induced by myocardial cellular damage during cardiac surgery may lead to myocardial stunning and apoptosis, and could therefore impair postoperative patient recovery. Surgical trauma typically induces the liberation of cytokines. Some of these cytokines are strongly associated with the initiation of intracellular proapoptotic pathways through activation of tyrosine kinases and integrins. The latter are known for their deteriorating effects on cardiac function and are strongly involved in cardiac remodeling. Dexamethasone is typically administered prior to cardiac surgery in order to especially reduce the release of proinflammatory cytokines. It has however never been investigated whether this additionally reduces proapoptotic signaling in the human heart, thereby eliminating risk factors for the induction of cardiac dysfunction. In the present study, the investigators therefore aim to investigate whether dexamethasone inhibits proapoptotic pathways in patients undergoing cardiac surgery. Furthermore, the investigators would like to elucidate whether this proposed effect of dexamethasone is related to the reduction of the stress response in the heart or indirectly by suppression of cytokine release. For this purpose the investigators will obtain cardiac biopsies and plasma from patients, who are randomly assigned to placebo or dexamethasone treatment and undergo on and off-pump coronary artery bypass grafting (CABG) surgery.

Registry
clinicaltrials.gov
Start Date
December 2008
End Date
June 2011
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Amsterdam UMC, location VUmc
Responsible Party
Principal Investigator
Principal Investigator

Christa Boer

Prof.dr. C. Boer

Amsterdam UMC, location VUmc

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing coronary artery bypass surgery (CABG)
  • Age 18-75 years
  • Informed consent

Exclusion Criteria

  • Re-operations and emergency operations
  • Patient with anemia (Hb \< 5.0)
  • Emergency operation
  • Patients receiving blood transfusions \< 3 months before operation
  • Insulin depended diabetes mellitus
  • Hepatic or renal failure
  • Pregnancy
  • Use of steroids

Arms & Interventions

1

High dose bolus of dexamethasone before surgery

Intervention: Dexamethasone

2

Placebo control

Intervention: Placebo

Outcomes

Primary Outcomes

Expression of p38 in cultured cells and cardiac tissue

Time Frame: One week

Secondary Outcomes

  • Pro-apoptotic signaling, precursor peptides of ANP (proANP), vasopressin (Copeptin), proET-1 and Adrenomedullin (proADM). Age, gender, length, body weight, hematocrit, Hb, leukocytes, surgery time, clamp time, CPB time(One week)

Study Sites (1)

Loading locations...

Similar Trials